Kellie Ryan

1.6k total citations
44 papers, 998 citations indexed

About

Kellie Ryan is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Kellie Ryan has authored 44 papers receiving a total of 998 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 11 papers in Pulmonary and Respiratory Medicine and 9 papers in Oncology. Recurrent topics in Kellie Ryan's work include Chronic Lymphocytic Leukemia Research (14 papers), Lung Cancer Treatments and Mutations (9 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Kellie Ryan is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Lung Cancer Treatments and Mutations (9 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Kellie Ryan collaborates with scholars based in United States, France and Japan. Kellie Ryan's co-authors include Carrie M. Kuehn, John Oxford, Jordana K. Schmier, W. Paul Glezen, Caroline Schaefer, Arthi Chandran, Gergana Zlateva, Parthiv J. Mahadevia, Matthew C. Hall and Stan L. Block and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Kellie Ryan

41 papers receiving 964 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Kellie Ryan 443 158 146 143 129 44 998
Reiko Sato 805 1.8× 56 0.4× 73 0.5× 16 0.1× 124 1.0× 66 1.3k
C. Verret 149 0.3× 47 0.3× 59 0.4× 55 0.4× 135 1.0× 69 1.0k
Aaron Saguil 134 0.3× 59 0.4× 63 0.4× 44 0.3× 95 0.7× 63 1.1k
Garret Cullen 674 1.5× 49 0.3× 32 0.2× 34 0.2× 101 0.8× 55 1.6k
Nathanaël Lapidus 337 0.8× 42 0.3× 62 0.4× 15 0.1× 270 2.1× 68 1.2k
Marie L. Borum 223 0.5× 27 0.2× 27 0.2× 72 0.5× 169 1.3× 152 1.3k
Sumona Saha 166 0.4× 49 0.3× 50 0.3× 20 0.1× 99 0.8× 68 907
Rebecca E. Chandler 106 0.2× 26 0.2× 85 0.6× 65 0.5× 112 0.9× 34 767
Maddalena Grazzini 201 0.5× 11 0.1× 153 1.0× 55 0.4× 96 0.7× 40 934
Martina L. Badell 225 0.5× 16 0.1× 57 0.4× 53 0.4× 82 0.6× 75 1.2k

Countries citing papers authored by Kellie Ryan

Since Specialization
Citations

This map shows the geographic impact of Kellie Ryan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kellie Ryan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kellie Ryan more than expected).

Fields of papers citing papers by Kellie Ryan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kellie Ryan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kellie Ryan. The network helps show where Kellie Ryan may publish in the future.

Co-authorship network of co-authors of Kellie Ryan

This figure shows the co-authorship network connecting the top 25 collaborators of Kellie Ryan. A scholar is included among the top collaborators of Kellie Ryan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kellie Ryan. Kellie Ryan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Flood, Emuella, et al.. (2025). Patient-Centered Real-World Evidence Framework for Oncology Product Development. Cancer Investigation. 43(10). 934–944.
2.
Roeker, Lindsey E., Maral DerSarkissian, Kellie Ryan, et al.. (2023). Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia. Blood Advances. 7(16). 4291–4301. 10 indexed citations
3.
DerSarkissian, Maral, et al.. (2023). Time and personnel costs associated with adverse event (AE) management among patients with chronic lymphocytic leukemia (CLL). Expert Review of Pharmacoeconomics & Outcomes Research. 23(6). 651–658.
4.
Barrientos, Jacqueline C., Ayed O. Ayed, Bruno Fang, et al.. (2023). Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences. Targeted Oncology. 18(5). 727–734. 1 indexed citations
5.
Munir, Talha, et al.. (2023). Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States. Expert Review of Pharmacoeconomics & Outcomes Research. 23(5). 579–589. 4 indexed citations
6.
Ryan, Kellie, et al.. (2021). Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects. Patient Preference and Adherence. Volume 15. 99–110. 10 indexed citations
7.
Hou, Jing‐Zhou, Kellie Ryan, Bruno Fang, et al.. (2021). Real-World Ibrutinib dose Reductions, Holds and Discontinuations in Chronic Lymphocytic Leukemia. Future Oncology. 17(35). 4959–4969. 17 indexed citations
8.
9.
10.
Ryan, Kellie, et al.. (2019). <p>The impact of initial antibiotic treatment failure: real-world insights in patients with complicated, health care-associated intra-abdominal infection</p>. Infection and Drug Resistance. Volume 12. 329–343. 21 indexed citations
11.
Ryan, Kellie, Ancilla W. Fernandes, Rajeshwari Punekar, et al.. (2019). Real-world outcomes in patients with unresected stage III non-small cell lung cancer. Medical Oncology. 36(3). 24–24. 19 indexed citations
12.
Ryan, Kellie, et al.. (2019). Treatment Patterns and Overall Survival among Patients with Unresectable, Stage III Non-Small-Cell Lung Cancer. Future Oncology. 15(29). 3381–3393. 13 indexed citations
13.
Ryan, Kellie, et al.. (2018). The impact of initial antibiotic treatment failure: Real-world insights in healthcare-associated or nosocomial pneumonia. Journal of Infection. 77(1). 9–17. 17 indexed citations
14.
Karve, Sudeep, et al.. (2017). The impact of initial antibiotic treatment failure: Real-world insights in patients with complicated urinary tract infection. Journal of Infection. 76(2). 121–131. 20 indexed citations
15.
Årdal, Christine, et al.. (2016). An assessment of the future impact of alternative technologies on antibiotics markets. Journal of Pharmaceutical Policy and Practice. 9(1). 34–34. 8 indexed citations
16.
Flood, Emuella, Kellie Ryan, Matthew D. Rousculp, et al.. (2011). A survey of children's preferences for influenza vaccine attributes. Vaccine. 29(26). 4334–4340. 42 indexed citations
17.
Winkelmann, Andreas, Serge Perrot, Caroline Schaefer, et al.. (2011). Impact of Fibromyalgia Severity on Health Economic Costs. Applied Health Economics and Health Policy. 9(2). 125–136. 73 indexed citations
18.
Knight, Tyler, et al.. (2010). Clinical and Economic Outcomes in Medicare Beneficiaries with Stage 3 or Stage 4 Chronic Kidney Disease and Anemia: The Role of Intravenous Iron Therapy. Journal of Managed Care Pharmacy. 16(8). 605–615. 10 indexed citations
19.
Perrot, Serge, Andreas Winkelmann, Ellen Dukes, et al.. (2010). Characteristics of patients with fibromyalgia in France and Germany. International Journal of Clinical Practice. 64(8). 1100–1108. 33 indexed citations
20.
Flood, Emuella, Matthew D. Rousculp, Kellie Ryan, et al.. (2010). Parents' decision-making regarding vaccinating their children against influenza: A web-based survey. Clinical Therapeutics. 32(8). 1448–1467. 99 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Reiko Sato Breakdown of academic impact, for papers by C. Verret Breakdown of academic impact, for papers by Aaron Saguil Breakdown of academic impact, for papers by Garret Cullen Breakdown of academic impact, for papers by Nathanaël Lapidus Breakdown of academic impact, for papers by Marie L. Borum Breakdown of academic impact, for papers by Sumona Saha Breakdown of academic impact, for papers by Rebecca E. Chandler Breakdown of academic impact, for papers by Maddalena Grazzini Breakdown of academic impact, for papers by Martina L. Badell
Rankless by CCL
2026